Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 1.00 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.42 |
| ▸ | TSHR | P16473 | 10/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.41 |
| ▸ | USP2 | O75604 | 8/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31615140 | 1.00 | S1PR1 (1.00) | S1PR1CETPCYP1A2ALDH1A1TSHR | |
| SCHEMBL2221025 | 0.91 | S1PR1 (0.83) | S1PR1CETPALDH1A1TSHRPPARG | |
| SCHEMBL2223368 | 0.91 | S1PR1 (0.83) | S1PR1CETPCYP1A2ALDH1A1TSHR | |
| SCHEMBL14797011 | 0.90 | S1PR1 (0.82) | S1PR1CETPCYP1A2ALDH1A1TSHR | |
| SCHEMBL2222062 | 0.90 | S1PR1 (0.82) | S1PR1CETPCYP1A2ALDH1A1PPARD | |
| SCHEMBL2222592 | 0.89 | S1PR1 (0.81) | S1PR1CETPPPARDPPARGFFAR1 | |
| SCHEMBL14797179 | 0.88 | S1PR1 (0.79) | S1PR1CETPCYP1A2PPARDPPARG | |
| SCHEMBL14797191 | 0.88 | S1PR1 (0.79) | S1PR1CETPPPARDPPARGLMNA | |
| SCHEMBL14797114 | 0.88 | S1PR1 (0.78) | S1PR1CETPPPARDPPARGFFAR1 | |
| SCHEMBL14797145 | 0.87 | S1PR1 (0.77) | S1PR1ALDH1A1PPARDPPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118697873-B | Use of S1PR 1-biased agonists in the treatment of inflammatory bowel disease | 四川大学华西医院 | 2026-05-12 | — | — | CN | claimed |
| CN-118697873-A | Use of S1PR 1-biased agonists in the treatment of inflammatory bowel disease | 四川大学华西医院 | 2024-09-27 | — | — | CN | claimed |
| EP-3057591-B1 | 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY | SANOFI SA (FR) | 2021-09-08 | — | — | EP | claimed |
| US-9782411-B2 | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury | SANOFI (FR) | 2017-10-10 | — | — | US | claimed |
| EP-3057591-A1 | 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY | SANOFI (FR) | 2016-08-24 | — | — | EP | claimed |
| US-20160235756-A1 | 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY | SANOFI (FR) | 2016-08-18 | — | — | US | claimed |
| WO-2015055694-A1 | 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY | SANOFI (FR) | 2015-04-23 | — | — | WO | claimed |
| EP-2862574-A1 | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury | SANOFI (FR) | 2015-04-22 | — | — | EP | claimed |
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2523962-B1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | claimed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | claimed |
| CN-122097375-A | Application of S1PR1 selective agonist SAR247799 in preparation of medicine for treating neuromyelitis Optica (OPYNAMIC) spectrum diseases | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122097375-A | Application of S1PR1 selective agonist SAR247799 in preparation of medicine for treating neuromyelitis Optica (OPYNAMIC) spectrum diseases | — | 2026-05-29 | — | — | CN | disclosed |
| CN-118697873-B | Use of S1PR 1-biased agonists in the treatment of inflammatory bowel disease | 四川大学华西医院 | 2026-05-12 | — | — | CN | disclosed |
| CN-118697873-B | Use of S1PR 1-biased agonists in the treatment of inflammatory bowel disease | 四川大学华西医院 | 2026-05-12 | — | — | CN | disclosed |
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2523962-B1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| EP-2523962-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086079-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, EDNRA, EDF1 | S1PR1 129/4885CETP 3150/4885CYP1A2 790/4885 |
| US-20160235756-A1 | 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY | REN, ATP6V1B1, AK2 | S1PR1 1817/4885CETP 4400/4885CYP1A2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.